All In Biotech

Drug Trial Radar · NCT05618808

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty

Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 373 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

373

Actual

Start

May 24, 2023

Primary completion

May 27, 2024

Study completion May 27, 2024

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin The secondary objectives of the study are: * To evaluate the bleeding risk (ie, major and clinically relevant non-major \[CRNM\] bleeding) of REGN9933 after unilateral TKA through time of venography, compared to enoxaparin * To assess overall safety and tolerability of REGN9933 in participants undergoing TKA * To evaluate the efficacy of REGN9933 in prevention of clinically relevant VTE, compared to enoxaparin * To evaluate the efficacy of REGN9933 in prevention of deep venous thrombosis (DVT) detected by venography, compared to enoxaparin * To evaluate the pharmacokinetics (PK) of REGN9933 after single intravenous (IV) administration * To assess pharmacodynamic (PD) effects of REGN9933 on intrinsic and extrinsic coagulation pathways * To assess immunogenicity following a single dose of REGN9933 over time * To compare the efficacy of enoxaparin and apixaban in prevention of VTE after unilateral TKA

Conditions

  • Venous Thromboembolism

Interventions

  • REGN9933Drug

    Participants will receive a single dose of REGN9933 by IV infusion

  • EnoxaparinDrug

    Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)

  • ApixibanDrug

    Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin)Time frame: Through Day 12

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Ziekenhuis Oost-Limburg- Campus Sint-Jan

    Genk, Limburg, Belgium

  • MBAL Heart and Brain Hospital

    Pleven, Bulgaria

  • Durham Bone and Joint Specialists

    Ajax, Ontario, Canada

  • Department of Orthopedics, Somogy County Mór Kaposi Teaching Hospital

    Kaposvár, Hungary

  • MAV Korhaz es Rendelointezet Szolnok

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Liepaja Regional Hospital

    Liepāja, Latvia

  • Vidzemes Hospital

    Riga, Latvia

  • Riga's 2nd Hospital

    Riga, Latvia

  • Hospital of Traumatology and Orthopaedics

    Riga, Latvia

  • Lietuvos Sveikatos Mokslu Universiteto Kauno Ligoninė

    Kaunas, Lithuania

  • Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinik

    Kaunas, Kaunas County, Lithuania

  • Klaipeda University Hospital

    Klaipėda, Klaipėda County, Lithuania

  • SP ZOZ Centralny Szpital Kliniczny UM w Lodzi

    Lodz, Poland

  • Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie

    Lublin, Poland

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Radzyniu Podlaskim

    Radzyń Podlaski, Poland

  • Specjalistyczny Szpital im. E. Szczeklika w Tarnowie

    Tarnów, Lesser Poland Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.